Mizuho Securities USA LLC Increases Position in Bristol-Myers Squibb (NYSE:BMY)

Mizuho Securities USA LLC increased its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 46.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 192,225 shares of the biopharmaceutical company's stock after acquiring an additional 60,759 shares during the period. Mizuho Securities USA LLC's holdings in Bristol-Myers Squibb were worth $10,872,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Fairway Wealth LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth $28,000. Darwin Wealth Management LLC bought a new stake in Bristol-Myers Squibb in the third quarter valued at $29,000. Comprehensive Financial Planning Inc. PA bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $34,000. Dunhill Financial LLC lifted its holdings in shares of Bristol-Myers Squibb by 39.8% in the 3rd quarter. Dunhill Financial LLC now owns 664 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 189 shares in the last quarter. Finally, Westend Capital Management LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at $38,000. 76.41% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, EVP Samit Hirawat acquired 1,823 shares of the company's stock in a transaction on Friday, February 14th. The stock was bought at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company's stock, valued at $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.09% of the stock is currently owned by company insiders.

Remove Ads

Bristol-Myers Squibb Price Performance

BMY traded down $0.02 during midday trading on Wednesday, hitting $59.18. The stock had a trading volume of 11,579,179 shares, compared to its average volume of 12,172,370. The business has a fifty day moving average of $58.36 and a 200 day moving average of $56.13. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The company has a market cap of $120.08 billion, a P/E ratio of -13.39, a price-to-earnings-growth ratio of 2.07 and a beta of 0.43. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, equities analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.19%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently -56.11%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BMY shares. Cantor Fitzgerald upped their target price on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Wells Fargo & Company boosted their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a report on Friday, February 7th. Truist Financial increased their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Bank of America restated a "neutral" rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Finally, Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a "hold" rating to a "buy" rating and boosted their target price for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $57.86.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.